Cognitive decline is a leading cause of disability and death in old age but its neurobiological bases are not well understood.
T ransactive response DNA-binding protein 43 (TDP-43) is the primary protein aggregate in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, 1, 2 but TDP-43 also forms pathologic aggregates in other proteinopathies such as Alzheimer disease (AD), 3 suggesting that it may contribute to cognitive dysfunction in these disorders. Immunoreactivity of TDP-43 is related to older age, 4, 5 with nearly half of older control participants in a recent study showing evidence of at least mild TDP-43 pathology, 5 suggesting that it may play a more prominent role in late-life cognitive decline than previously recognized. However, few studies of TDP-43 have included measurement of cognitive function 4, [6] [7] [8] [9] and these have been based on a single point in time rather than direct assessment of change. In addition, TDP-43 is associated with other neuropathologic conditions, such as AD 3, [8] [9] [10] and hippocampal sclerosis, 4, 9, 10 and it is uncertain whether TDP-43 has an association with cognitive functioning that is independent of these other pathologic processes. 9 The present study tested the hypothesis that TDP-43 pathology is related to cognitive decline in old age. Participants were older Catholic nuns, priests, and monks without dementia at study entry who completed annual cognitive testing for a mean of 10.1 years prior to death. On neuropathologic examination, immunohistochemical measures of TDP-43 pathology and other neurodegenerative markers were collected from multiple brain regions, and the presence of infarcts and hippocampal sclerosis was determined. In analyses, we tested for the hypothesized association of TDP-43 with cognitive decline, examined whether other pathological conditions could account for the association, compared the cognitive profile of TDP-43 with profiles of other conditions, and assessed whether TDP-43 was elevated in mild cognitive impairment and dementia.
Methods

Participants
We used data from persons in the Religious Orders Study, a longitudinal clinical-pathologic investigation of older Catholic nuns, priests, and brothers recruited from more than 40 groups across the United States. 11, 12 Eligibility required age older than 55 years, absence of a prior dementia diagnosis, and agreement to annual clinical evaluations (begun in 1994 and continuing) and organ donation at death. All participants signed an informed consent and anatomic gift act. The project was approved by the institutional review board of Rush University Medical Center. At the time of these analyses, 539 of 1081 study participants without baseline dementia had died. Of these, 505 (94%) had undergone a brain autopsy, which had been completed in the first consecutive 490, of whom 463 had longitudinal cognitive data. Of these, TDP-43 data had been collected in 130. Compared with the 333 without TDP-43 data, the 130 with TDP-43 had more follow-up (10.1 years vs 8.7 years; χ 2 1 = 17.7; P < .001) but did not differ in age, sex, education, global cognition (at baseline or proximate to death), postmortem interval, amyloid plaques, tangles, hippocampal sclerosis, neocortical Lewy bodies, or cerebral infarcts. They died at a mean (SD) age of 88.1 (7.5) years after a mean (SD) of 10.1 (3.1) years of annual cognitive testing. They had completed a mean (SD) of 18.0 (3.3) years of education and 70.8% were women.
Assessment of Cognitive Function
Cognition was assessed annually with a battery of 20 tests that are described in Table 1 . To minimize measurement error, we used composite cognitive measures in most analyses. We formed a composite measure of global cognition that used all 20 tests and based in part on previous factor analyses in this 13 and other 14, 15 cohorts, composite measures of episodic memory (based on 7 tests), semantic memory (4 tests), working memory (4 tests), perceptual speed (2 tests), and visuospatial ability (2 tests). Scores on individual tests were converted to z scores, using the baseline mean and standard deviation, and the z scores were averaged to yield each composite. We also analyzed change in the raw scores of each individual test.
Clinical Evaluation
The annual evaluations also included a medical history and neurological examination. [11] [12] [13] After each evaluation, an experienced clinician diagnosed dementia and mild cognitive impairment. Classification of dementia required a history of cognitive decline and impairment in at least 2 cognitive domains. 16 To maintain uniformity in the diagnostic process, we used an algorithm to rate impairment in 5 cognitive domains (orientation, attention, memory, language, and perception) based on educational level and scores on 11 of the cognitive tests. 17 After review of all cognitive data, a neuropsychologist agreed or disagreed with each algorithmic rating and supplied new ratings in the event of disagreements. The diagnosis of mild cognitive impairment required impairment in 1 or more cognitive domains in the absence of dementia. 17 On death, all clinical data were reviewed by a board-certified neurologist blinded to all pathologic data and final diagnoses of mild cognitive impairment and dementia were made.
Neuropathologic Examination
The brain was removed a median of 5.5 hours (interquartile range, 5.4 hours) after death, which occurred a median of 7.7 months (interquartile range, 7.0 months) following the last clinical evaluation. One cerebral hemisphere, one cerebellar hemisphere, and the brainstem were fixed in 4% paraformaldehyde for at least 72 hours. The brain was cut coronally into 1-cm slabs and all slabs were examined for gross infarcts. A standard protocol was followed for tissue preservation, tissue sectioning, and quantification of pathologic data by examiners blinded to all clinical data. 18, 19 We used hematoxylin and eosin to identify microinfarcts (ie, visible on microscopic but not gross inspection) in 9 regions in 1 hemisphere, as previously described. 20 In analyses, chronic gross and microscopic infarcts were each treated as present or absent. Based on prior research, 1,21-26 we investigated TDP-43 pathology in 6 brain regions: the amygdala (and periamygdalar region, when available), hippocampus CA1/subiculum, dentate gyrus, entorhinal cortex, midfrontal cortex, and middle temporal cortex. Immunostaining was done on 6-μm sec-tions using monoclonal antibodies to phosphorylated TDP-43 (pS409/410; 1:100), 27 which stain the pathologically phosphorylated TDP-43 proteins in the inclusions seen in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and other neurodegenerative diseases but not the normal nuclear TDP-43. Each region of interest was reviewed for the presence, severity, and location of TDP-43 cytoplasmic inclusions (both neuronal and glial) and was rated on a 6-point scale based on the number of inclusions in a 0. Figure 1 ). An antipaired helical filaments-tau antibody clone AT8 (ThermoScientific; 1:2000) and computer-assisted sampling 28 were used to measure density of tau-immunoreactive neurofibrillary tangles in at least 2 sections from 8 limbic and neocortical regions (entorhinal cortex, CA1/subiculum, anterior cingulate cortex, dorsolateral prefrontal cortex, superior frontal cortex, inferior temporal cortex, inferior parietal cortex, and primary visual cortex). The raw scores in each section and region were averaged to yield a composite measure of tangle density per square millimeter, as previously described. 26 Beta-amyloid-immunoreactive plaques were assessed in the 8 regions examined for tau using a monoclonal antibody (1:50; beta-amyloid, Clone 6F/3D, Dako) with diaminobenzidine as the reporter, with 2.5% nickel sulfate to enhance contrast. Computer-assisted sampling and image analysis were used to quantify the percentage of each area occupied by betaamyloid-immunoreactive pixels. Regional measures were averaged to yield a composite measure of amyloid burden. 28 Lewy bodies were identified in the substantia nigra, 2 limbic sites (entorhinal cortex and anterior cingulate cortex), and 3 neocortical sites (midfrontal cortex, superior or middle temporal cortex, and inferior parietal cortex) using a monoclonal antibody to alpha-synuclein (Zymed LB 509; 1:50). 18 We used a modified version 29, 30 of the staging criteria of McKeith et al 31 to classify Lewy body disease as nigral, limbic, or neocortical. Neocortical disease required Lewy bodies in the frontal, temporal, or parietal cortex and was usually accompanied by nigral and limbic Lewy bodies.
Statistical Analysis
To assess agreement among TDP-43 raters, we calculated the component of variance owing to rater as a fraction of the total variance for each brain region. The dimensionality of the re- 
Results
As shown in Table 2 , the regional measures of TDP-43 were positively skewed, with no TDP-43 pathology in 54% and levels ranging from sparse to severe in the remaining 46%.
Transactive response DNA-binding protein 43 pathology was most common in the amygdala (45%), less common in the entorhinal cortex (22%) and hippocampus (16%-21%), and least common in the neocortex (5%-10%). None of those with neocortical TDP-43 pathology had degeneration of the frontal or temporal lobes plus layer 2 spongiform changes compatible with a diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions. 34 The intraclass correlation coefficients of the regional measures, based on independent ratings of an approximate 8% subset of slides by 3 individuals, indicate good interrater reliability (Table 2 ). In a principal-components analysis, the regional TDP-43 measures loaded on a single factor that accounted for 63.3% of the variance ( 39 .2% had at least 1 chronic gross infarct, 28.5% had at least 1 chronic microinfarct, 7.7% had neocortical Lewy bodies, and 9.2% had hippocampal sclerosis. The presence of TDP-43 pathology was associated with higher amyloid plaque burden, tangle density, and likelihood of hippocampal sclerosis but not with likelihood of gross infarcts, microinfarcts, or neocortical Lewy bodies (eTable 2 in Supplement).
TDP-43 and Global Cognitive Decline
The top panel of Figure 2 , which shows the rate of global cognitive decline plotted by level of TDP-43 fit with a Loess, suggests that the association of TDP-43 with the rate of cognitive decline is approximately linear and supports the use of linear mixed-effects models. In the initial analysis, there was a mean decline of 0.073 units per year in the global cognitive measure (standard error [SE], 0.012; P < .001). Higher levels of TDP-43 inclusions were associated with lower levels of global cognition (estimate, −0.090; SE, 0.021; P < .001) and more rapid global cognitive decline (estimate, −0.010; SE, 0.002; P < .001). Because TDP-43 was associated with amyloid plaques, tangles, and hippocampal sclerosis, we repeated the analysis with terms added for these pathologic measures. In this model, TDP-43 (estimate, −0.006; SE, 0.002; P = .007) and tangles (estimate, −0.007; SE, 0.002; P < .001) were each related to more rapid cognitive decline with no association for amyloid (estimate, −0002; SE, 0.004; P = .60) or hippocampal sclerosis (estimate, −0.048; SE, 0.037; P = .20). The bottom panel of Figure 2 , which is based on this analysis, suggests a doseresponse relationship with higher levels of TDP-43 pathology associated with increasingly rapid cognitive decline.
In further analyses, we compared the impact of TDP-43 and tangles on cognitive aging. Relative to a model adjusted for age at death, TDP-43 accounted for an additional 21% of the variance in rates of cognitive decline vs 26% for tangles. With tangles in the model, TDP-43 accounted for an additional 12% of the variance vs 16% for tangles with TDP-43 in the model.
TDP-43 and Decline in Cognitive Domains
To determine whether TDP-43 was related to decline in some cognitive functions but not others, we assessed change in 5 different cognitive domains ( Table 3) . A higher level of TDP-43 pathology was associated with more rapid decline in episodic memory and working memory but not with decline in other domains. In contrast, tangle density was associated with decline in all domains, amyloid plaque burden was not related to decline in any domain, and hippocampal sclerosis was associated with decline in semantic memory but not other domains.
We conducted additional analyses with the individual tests as outcomes instead of composite measures. For each test, Table 1 shows the mean score at baseline, the mean score proximate to death, and the estimated annual rate of change. In the analyses (eTable 2 in Supplement), TDP-43 was related to decline on all 7 episodic memory tests, the Boston Naming Test, Digit Span Forward, and the Mini-Mental State Examination. Tangle density was associated with decline on 15 tests, amyloid plaque burden with decline on 2 tests (immediate story recall and Boston Naming Test), and hippocampal sclerosis The top panel shows the individual rates of global cognitive decline, adjusted for age at death, plotted by level of TDP-43 pathology, and fitted with a locally reweighted linear smooth function. The bottom panel shows the 10-year paths of global cognitive decline in typical participants with no TDP-43 pathology (solid line) and with low (long dashes, 10th percentile), moderate (short dashes, 50th percentile), or high (dotted line, 90th percentile) levels of TDP-43 pathology, adjusted for age at death, amyloid, tangles, and hippocampal sclerosis. 
TDP-43 and Clinical Diagnoses
Proximate to death, 38 participants (29%) had no evidence of cognitive impairment, 39 (30%) had mild cognitive impairment, and 53 (41%) had dementia. To determine whether TDP-43 was differentially related to cognition along the spectrum from intact function to dementia, we examined its relation to clinical diagnosis. In an analysis that included terms for age at death, amyloid plaques, and tangles, a higher level of TDP-43 pathology was associated with a higher likelihood of dementia relative to mild cognitive impairment (χ 
Discussion
A cohort of 130 older persons without dementia at study entry underwent annual cognitive testing for a mean of about 10 years during which more than 40% developed dementia. On neuropathologic examination, TDP-43 pathology was identified in nearly half of the participants, and it accounted for nearly as much of the variability in the rates of cognitive decline as did AD pathology. The findings suggest that TDP-43 is an important pathology underlying late-life cognitive decline and dementia.
In previous research, TDP-43 pathology has been associated with a lower level of global cognition 4, 6, 8 and higher likelihood of dementia. 9 The present results extend these observations in 2 important ways. First, the association of TDP-43 with lower levels of global cognition persisted after controlling for age, AD pathology, and hippocampal sclerosis, supporting the idea that its association with cognitive impairment is relatively independent of these other pathologic processes. Second, after controlling for this association, age, and other pathologies, TDP-43 was associated with more rapid cognitive decline. That it accounted for nearly as much of the variability in cognitive decline as neurofibrillary tangles suggests that TDP-43 pathology plays a substantial role in latelife loss of cognition. The manner in which TDP-43 pathology leads to impaired neuronal function is not known. Multiple pathways activated by TDP-43 aggregation may be involved, but the downstream consequences of TDP-43 phosphorylation, aggregation, cleavage, mislocalization, and clearance from the nucleus are still unclear. 35 The clearance of normal TDP-43 from the nucleus may represent a loss of normal TDP-43 that leads to neurodegeneration, or, alternatively, the retention of TDP-43 in cytoplasmic aggregates could sequest diverse RNAs and thereby lead to neurodegeneration through a toxic gain of function.
35
Whether TDP-43 pathology has a characteristic cognitive profile is not known. To our knowledge, few TDP-43 studies have assessed multiple cognitive functions 4,7-9 and results have been inconsistent. For example, TDP-43 was associated with impairment of semantic memory but not episodic memory in one study, 4 whereas another study reported the opposite pattern. 8 This inconsistency may reflect several factors including reliance on cross-sectional cognitive data and the potentially confounding effects of other pathologic processes on cognition. In the present study, TDP-43 was associated with impairment and decline in multiple cognitive domains. However, after adjustment for AD pathology and hippocampal sclerosis, TDP-43 pathology was related to decline in episodic and working memory but not to decline in other cognitive domains. The cognitive profile associated with TDP-43 pathology differed from the cognitive profiles associated with AD pathology and hippocampal sclerosis. Consistent with prior research, 1,21-26 TDP-43 pathology was most common in the medial temporal lobe, which may account for its robust association with episodic memory dysfunction. In this cohort, TDP-43 pathology was increased in persons with dementia but not in those with mild cognitive impairment. This suggests that TDP-43 may be more strongly related to progression of cognitive symptoms than to their initial development, or that it is a separate age-related process that is age shifted, occurring in most instances after the onset of other age-related neurodegenerative processes. In contrast, the pathologic processes traditionally associated with late-life dementia (eg, tangles, Lewy bodies, and cerebral infarcts) appear to account for more of the variability in incipient cognitive decline than in later acceleration of decline. [36] [37] [38] [39] Study strengths and limitations should be noted. A uniform clinical evaluation and established criteria were used to clinically classify individuals. Participation in annual follow-up and autopsy was high, minimizing risk for bias owing to selective attrition. The availability of a mean of approximately 10 years of annual cognitive assessments with psychometrically established measures allowed us to reliably estimate individual trajectories of cognitive change. Because of the selected nature and relatively small size of the group studied, it will be important to replicate these findings. In addition, use of a nonphosphorylated epitope rather than a phosphorylated antibody probably resulted in underestimation of the burden of synucleinopathy.
